FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022145741> ?p ?o ?g. }

• W2022145741 endingPage "2582" @default.
• W2022145741 startingPage "2576" @default.
• W2022145741 abstract "Objective: Selective cyclooxygenase-2 inhibition by rofecoxib was associated with increased risk of cardiovascular events. We hypothesized that concomitant treatment with thromboxane prostanoid receptor antagonist S18886 might ameliorate possible negative effects. We evaluated the effects of S18886, rofecoxib, and the interaction of both compounds in a combined treatment on myocardial infarct (MI) size and cardiac function after experimental ischemia/reperfusion injury in hyperlipidemic APOE*3Leiden transgenic mice. Design: Prospective, randomized, control trial. Setting: Research laboratory. Subjects: Hyperlipidemic APOE*3Leiden transgenic mice. Interventions: After four weeks of feeding an atherogenic diet, MI was induced by a 30-min ligation of the left anterior descending coronary artery, followed by reperfusion. Oral compound treatment was initiated 90 mins before MI, and continued daily by gavage for seven days. Four treatment groups (n = 12, each) were studied: solvent (Control), S18886, rofecoxib, and S18886 plus rofecoxib. Measurements and Main Results: One week after MI, the mice were anesthetized and cardiac function was quantified by left ventricular (LV) pressure-volume relationships obtained by miniature pressure-conductance catheters. The ischemic area was measured by morphometry and expressed as percentage of LV area. No significant differences in infarct size were found between groups. Compared with control, treatment with S18886 did not affect heart function whereas the rofecoxib group had significantly lower cardiac output (4.5 ± 0.8 vs. 3.2 ± 1.1 mL/min, p < 0.01), lower ejection fraction (40 ± 8 vs. 27 ± 11%, p < 0.005), and increased end-systolic volume (18.6 ± 5.7 vs. 28.6 ± 9.0 μL, p < 0.05). The group with combined (S18886+rofecoxib) treatment was not different from control. Statistical analysis showed significant interactive effects between S18886 and rofecoxib indicating that negative effects of rofecoxib on cardiac function were prevented by S18886 treatment. Conclusions: Rofecoxib treatment reduced global and systolic LV function after ischemia-reperfusion injury in APOE*3Leiden mice. These negative effects are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)." @default.
• W2022145741 created "2016-06-24" @default.
• W2022145741 creator A5005451442 @default.
• W2022145741 creator A5010369401 @default.
• W2022145741 creator A5018228783 @default.
• W2022145741 creator A5039135934 @default.
• W2022145741 creator A5039820373 @default.
• W2022145741 creator A5065617132 @default.
• W2022145741 creator A5074091229 @default.
• W2022145741 date "2008-09-01" @default.
• W2022145741 modified "2023-10-17" @default.
• W2022145741 title "Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)*" @default.
• W2022145741 cites W1969016210 @default.
• W2022145741 cites W1990082411 @default.
• W2022145741 cites W2010861717 @default.
• W2022145741 cites W2012722118 @default.
• W2022145741 cites W2014769233 @default.
• W2022145741 cites W2016071225 @default.
• W2022145741 cites W2026818910 @default.
• W2022145741 cites W2030294437 @default.
• W2022145741 cites W2030939387 @default.
• W2022145741 cites W2031866289 @default.
• W2022145741 cites W2047024906 @default.
• W2022145741 cites W2047031629 @default.
• W2022145741 cites W2070161415 @default.
• W2022145741 cites W2082001748 @default.
• W2022145741 cites W2085698001 @default.
• W2022145741 cites W2088179332 @default.
• W2022145741 cites W2099450181 @default.
• W2022145741 cites W2099861108 @default.
• W2022145741 cites W2100631748 @default.
• W2022145741 cites W2102243792 @default.
• W2022145741 cites W2105924650 @default.
• W2022145741 cites W2120167551 @default.
• W2022145741 cites W2124939010 @default.
• W2022145741 cites W2126335694 @default.
• W2022145741 cites W2130963215 @default.
• W2022145741 cites W2135393211 @default.
• W2022145741 cites W2139776244 @default.
• W2022145741 cites W2150883191 @default.
• W2022145741 cites W2158131645 @default.
• W2022145741 cites W2158968701 @default.
• W2022145741 cites W2163149796 @default.
• W2022145741 cites W2330496155 @default.
• W2022145741 cites W4255226843 @default.
• W2022145741 cites W5975269 @default.
• W2022145741 cites W2320577816 @default.
• W2022145741 doi "https://doi.org/10.1097/ccm.0b013e318183f0fd" @default.
• W2022145741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18679128" @default.
• W2022145741 hasPublicationYear "2008" @default.
• W2022145741 type Work @default.
• W2022145741 sameAs 2022145741 @default.
• W2022145741 citedByCount "12" @default.
• W2022145741 countsByYear W20221457412012 @default.
• W2022145741 crossrefType "journal-article" @default.
• W2022145741 hasAuthorship W2022145741A5005451442 @default.
• W2022145741 hasAuthorship W2022145741A5010369401 @default.
• W2022145741 hasAuthorship W2022145741A5018228783 @default.
• W2022145741 hasAuthorship W2022145741A5039135934 @default.
• W2022145741 hasAuthorship W2022145741A5039820373 @default.
• W2022145741 hasAuthorship W2022145741A5065617132 @default.
• W2022145741 hasAuthorship W2022145741A5074091229 @default.
• W2022145741 hasConcept C111566952 @default.
• W2022145741 hasConcept C126322002 @default.
• W2022145741 hasConcept C134018914 @default.
• W2022145741 hasConcept C164705383 @default.
• W2022145741 hasConcept C170493617 @default.
• W2022145741 hasConcept C181199279 @default.
• W2022145741 hasConcept C185592680 @default.
• W2022145741 hasConcept C2776785769 @default.
• W2022145741 hasConcept C2778198053 @default.
• W2022145741 hasConcept C2778266237 @default.
• W2022145741 hasConcept C2778582115 @default.
• W2022145741 hasConcept C2779689624 @default.
• W2022145741 hasConcept C2780114680 @default.
• W2022145741 hasConcept C2780664492 @default.
• W2022145741 hasConcept C2781024287 @default.
• W2022145741 hasConcept C42219234 @default.
• W2022145741 hasConcept C500558357 @default.
• W2022145741 hasConcept C541997718 @default.
• W2022145741 hasConcept C55493867 @default.
• W2022145741 hasConcept C71924100 @default.
• W2022145741 hasConcept C78085059 @default.
• W2022145741 hasConcept C89560881 @default.
• W2022145741 hasConceptScore W2022145741C111566952 @default.
• W2022145741 hasConceptScore W2022145741C126322002 @default.
• W2022145741 hasConceptScore W2022145741C134018914 @default.
• W2022145741 hasConceptScore W2022145741C164705383 @default.
• W2022145741 hasConceptScore W2022145741C170493617 @default.
• W2022145741 hasConceptScore W2022145741C181199279 @default.
• W2022145741 hasConceptScore W2022145741C185592680 @default.
• W2022145741 hasConceptScore W2022145741C2776785769 @default.
• W2022145741 hasConceptScore W2022145741C2778198053 @default.
• W2022145741 hasConceptScore W2022145741C2778266237 @default.
• W2022145741 hasConceptScore W2022145741C2778582115 @default.
• W2022145741 hasConceptScore W2022145741C2779689624 @default.
• W2022145741 hasConceptScore W2022145741C2780114680 @default.
• W2022145741 hasConceptScore W2022145741C2780664492 @default.

• next